How long will the good times roll for medtech?
The entry of non-traditional funders – and the availability of non-traditional exits – has altered medtech, though probably only temporarily.
Medtech venture funding hits new heights
Private device makers enjoy the biggest quarter for four years – and the average deal is larger than ever.
Venture investors still love drug developers
Biopharma scores a $5bn quarter as another big year builds for venture financing.
Biopharma and venture capital: a deep dive
Find out where the venture money has been flowing in our new report on biopharma investment trends, free to download now.
Kizoo aims to cure ageing
The German tech investor Kizoo Ventures is committing €300m of its own cash to biotech start-ups working on rejuvenation and healthy lifespan expansion.
Medtech venture backers go in early
A sudden increase in seed and series A funding bodes well for the year ahead.
Abingworth taps biopharma’s appetite for risk-sharing
The success of previous forays into the clinical co-development space has enabled the UK venture firm to raise its biggest fund yet.
Europe’s venture boom trails the US
But financing sizes have grown by a similar amount on both sides of the Atlantic.
